Navigation Links
H3 Biomedicine and Selvita Announce Strategic Collaboration to Develop Precision Cancer Medicines
Date:9/16/2013

iomedicine.com/leadership#Warmuth">Markus Warmuth, M.D., President and Chief Executive Officer, H3 Biomedicine. "Both H3 Biomedicine and Selvita value early validation of drug targets to achieve preclinical proof of concept followed by translation of these findings into novel therapies for targeted patient populations. This collaboration is a key tool in our arsenal as it brings Selvita's kinase biology platform and medicinal chemistry capabilities together with H3's expertise in target validation, bioinformatics and genomics analysis. We look forward to working with Selvita to ultimately bring efficacious medicines to patients."

Pawel Przewiezlikowski, Chief Executive Officer of Selvita, said, "We are delighted to enter into this collaboration with H3 Biomedicine, and to apply our kinase discovery platform to jointly advance target discovery. The unique target identification and validation competences of H3 will bring our discovery efforts to a new level."

Krzysztof Brzozka, Chief Scientific Officer of Selvita, added "Both H3 and Selvita teams have always strived to identify novel therapeutic solutions for people living with cancer and we are very pleased that we can now join forces. This collaboration will enable us to significantly increase the breadth and depth of our pipeline."

About H3 Biomedicine Inc.
H3 Biomedicine is a biopharmaceutical company specializing in the discovery and development of oncology treatments. Using modern synthetic chemistry, chemical biology and human genetics, the company seeks to bring the next generation of cancer treatments to market with the goal of improving the lives of patients. H3 Biomedicine is based in Cambridge, Massachusetts. Visit http://www.h3biomedicine.com/ for more information.

About Selvita
Selvita is a Polish biotechnology company engaged in the discovery and developme
'/>"/>

SOURCE H3 Biomedicine Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cellular Biomedicine Group Reports Second Quarter and First Half 2013 Financial Results and Business Highlights
2. Cellular Biomedicine Group Announces Expansion in the Osteoarthritis and Rheumatoid Arthritis Market
3. Cellular Biomedicine Group Announces Appointment of Corporate Controller
4. Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis
5. Cellular Biomedicine Group Provides Update and 2013 Milestones
6. Cellular Biomedicine Group Appoints Dr. Jianping Dai to the Board of Directors
7. Cellular Biomedicine Group President Presents Keynote Address at New York Stem Cell Summit
8. Cellular Biomedicine Group Announces ISO 9001:2008 Certification and ISO-14644 Cleanroom Certification
9. EastBridge Investment Group Announces Completion of its Merger with Cellular Biomedicine Group - Shareholder Conference Call to be held February 8th
10. H3 Biomedicine Expands Cambridge Facilities, Doubles Employee Base as Scientific Program Advances
11. A 300 Million Euro Boost for Biomedicine in Berlin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... AZ (PRWEB) July 31, 2014 Sales ... availability of its online sales training course – ... improve their sales performance. , Drawn from proven sales ... 500 companies, Mastering the Complex Sale online sales training ... to anyone who has face-to-face contact with customers, like ...
(Date:7/30/2014)... PARIS , July 30, 2014 /PRNewswire/ ... and NYSE: SNY) today announced that the Companies intend ... rare pediatric disease priority review voucher in connection with ... priority review voucher entitles the holder to designate a ... 6-month review from the filing date instead of the ...
(Date:7/30/2014)... , July 30, 2014  Decision Resources Group ... medical directors in the United States ... biosimilar market penetration will be the level of ... and the expected lower cost to patients. Payers ... that meet their pricing expectations in order to ...
(Date:7/30/2014)... 30, 2014  The Chicago Bears are excited to ... Dermatology (Academy) in an effort to raise awareness of ... host free SPOT me™ skin cancer screenings at a ... Field. SPOT me™ is an educational campaign designed ... and risks of skin cancer, and encourages people to ...
Breaking Biology Technology:Sales Horizons Offers Mastering the Complex Sale - a Comprehensive, Online Sales Skills Training Course 2Sales Horizons Offers Mastering the Complex Sale - a Comprehensive, Online Sales Skills Training Course 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 2Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 4Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 5Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 6Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 2Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 3Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 2Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 3Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 4
... March 23, 2011 Advanced Cell Technology, Inc. ("ACT"; ... in the field of regenerative medicine, announced today that ... Company,s patent application to provide broad intellectual property protection ... retinal pigment epithelial (RPE) cells from human embryonic stem ...
... of survival tend to favor the strongest, but University ... world of self-healing materials, it is the somewhat frail ... Langmuir a new model laying out the ... particles that can regenerate after taking damage and are ...
... NEOG ) announced today that its net income ... 28, increased 27% from the previous year to $4,943,000 — ... $0.17 per share. Third quarter revenues increased ... company, compared to the prior year,s $33,833,000. Year to date, ...
Cached Biology Technology:ACT to Be Issued Broad Patent for Human ES Cell-derived RPE Cells in China 2ACT to Be Issued Broad Patent for Human ES Cell-derived RPE Cells in China 3Only the weak survive?: Pitt team adds more give for stronger self-healing materials 2Neogen Reports 27% Increase in Quarterly Net Income 2Neogen Reports 27% Increase in Quarterly Net Income 3Neogen Reports 27% Increase in Quarterly Net Income 4Neogen Reports 27% Increase in Quarterly Net Income 5Neogen Reports 27% Increase in Quarterly Net Income 6
(Date:7/30/2014)... Antonio Life Sciences Institute (SALSI), a joint venture between ... The University of Texas Health Science Center at San ... Pilot Program. The winners, Emily Boice from UTSA and ... $25,000 for their project titled, "Novel engineered ferritins for ... , Boice and Huang,s research is focused on finding ...
(Date:7/30/2014)... baboons suggests that the route to a higher rank is ... of supportive sisters. , A female baboon,s social status is ... of her mother - the higher the mother is ranked, ... rank in female baboons is thought to be determined at ... spot in the pecking order, whereas females born to low-ranking ...
(Date:7/30/2014)... University associate professor Andrew S. Mount, performed cutting-edge research ... for novel anti-fouling paint for ships and boats and ... The team,s findings, published in Nature Communications ... that attaches to a wide variety of surfaces using ... an underwater heavy-duty adhesive. , "In previous research, we ...
Breaking Biology News(10 mins):Supportive moms and sisters boost female baboon's rank 2Supportive moms and sisters boost female baboon's rank 3Study: Marine pest provides advances in maritime anti-fouling and biomedicine 2
... PHILADELPHIA The second American Association for Cancer ... Research: From the Laboratory to the Clinic provides attendees ... in a variety of fields, including the tumor microenvironment, ... takes place March 7-10, 2010, at the King Hussein ...
... of America is pleased to announce the 2010 Yeast ... at the University of British Columbia (UBC) in Vancouver, ... various aspects of eukaryotic biology in yeast. Program ... Canadian astronaut who is also a Member of Parliament. ...
... Texas Imagine a mosquito-borne virus that has already infected ... Asia, the islands of the Indian Ocean, Africa and northern ... that can linger for months or even years. It,s capable ... much of North America. And no vaccine or treatment exists ...
Cached Biology News:The AACR to host second cancer research conference in Jordan 22010 Yeast Genetics and Molecular Biology Meeting 22010 Yeast Genetics and Molecular Biology Meeting 3Experimental vaccine protects monkeys against chikungunya 2
... - Proliferation Marker, prediluted Ki67 antigen ... protein, expressed by proliferating cells in all ... S, G2 and M phase). It is ... are useful in establishing the cell growing ...
... 100 g of monoclonal antibody reactive against ... of SURF1 are highest in growing cultured cells. ... c oxidase which is thought to participate in ... insertion into this subunit. Mutations of SURF1, particularly ...
Phenytoin-BSA Isolated IgY DFc Drug...
Annexin V Binding Buffer, 10X Concentrate Buffer , 50 ml Consult technical datasheet for details....
Biology Products: